Samsung Biologics Highlights ADC Manufacturing Strength

Mark Studer, head of Samsung Biologics’ ADC and mRNA Operations Team, delivers a presentation on the company’s efforts and achievements in securing ADC commercial manufacturing capabilities at "World ADC San Diego 2026" held in San Diego, California, on Oct. 14 local time. Operates Full ADC Process at Single Songdo Site, Launched Dedicated Facility in March 2025 and Plans DP Line by 2027 Samsung Biologics participated in "World ADC San Diego 2026," held for four days from October 12 to 15 in San Diego, California. Marking its third consecutive year operating a standalone booth, Samsung Biologics presented its end-to-end one-stop service capabilities spanning Contract Research Organization (CRO), Contract Development Organization (CDO), and Contract Manufacturing Organization (CMO) services to the global market. The company highlighted as its core competitiveness its ability to carry out the entire ADC manufacturing process at a single site in Songdo, Incheon, based on its existing antibody drug manufacturing capabilities. Samsung Biologics entered the market in earnest by launching a dedicated ADC production facility in March 2025, and it now has comprehensive capabilities covering the full process from cell line development to conjugation, analysis, and manufacturing. It also detailed plans to expand its production infrastructure. Samsung Biologics said it plans to establish and begin operating a dedicated ADC drug product (DP) line by 2027. Through this, the company aims to further strengthen its end-to-end service system to respond flexibly to diverse customer demand. During a presentation session held at the event, the company introduced achievements related to expanding ADC GMP manufacturing scale. Mark Studer, head of the ADC and mRNA Operations Team, explained Samsung Biologics’ manufacturing competitiveness by sharing plans to expand biopharmaceutical conjugation services and key success factors for securing commercial production capabilities. Research achievements aimed at technical differentiation were also disclosed through poster presentations. Kim Ji-na, head of the ADC Platform Discovery Group, presented development results using the bispecific antibody platform "S-DUAL®," while Oh Se-gyu, a professional at the Organoid Technology Group, presented evaluation results for "Samsung Organoid," a patient-derived organoid (PDO)-based drug screening service. Lee Sang-myung, Executive Vice President and Head of CDO Development at Samsung Biologics, said, "Through this event, we showcased our CDMO capabilities to meet diversifying customer demand, including for ADCs and bispecific antibodies," adding, "Going forward, we will continue to expand capabilities related to new modalities such as peptides to solidify our end-to-end response capabilities."